Mostrar 1 - 6 resultats de 6 per cerca 'Flynt, E', hora de la petició: 0.02sec
Refinar resultats
-
1
-
2
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma per Amatangelo, M, Flynt, E, Stong, N, Ray, P, Van Oekelen, O, Wang, M, Ortiz, M, Maciag, P, Peluso, T, Parekh, S, van de Donk, NWCJ, Lonial, S, Thakurta, A
Publicat 2024Journal article -
3
Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients per Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Salazar, MA, Fitzsimons, E, Estevez, MO, Towfic, F, Flynt, E, Pierceall, WE, Yong, K, Vyas, P, Thakurta, A
Publicat 2021Conference item -
4
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma per Gooding, S, Ansari-Pour, N, Towfic, F, Ortiz Estévez, M, Chamberlain, PP, Tsai, K-T, Flynt, E, Hirst, M, Rozelle, D, Dhiman, P, Neri, P, Ramasamy, K, Bahlis, N, Vyas, P, Thakurta, A
Publicat 2020Journal article -
5
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma per Van Oekelen, O, Amatangelo, M, Guo, M, Upadhyaya, B, Cribbs, AP, Kelly, G, Patel, M, Kim-Schulze, S, Flynt, E, Lagana, A, Gooding, S, Merad, M, Jagganath, S, Pierceall, WE, Oppermann, U, Thakurta, A, Parekh, S
Publicat 2024Journal article -
6
Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma per Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Polonskaia, A, Angulo Salazar, M, Fitzsimons, E, Sirinukunwattana, K, Chavda, SJ, Ortiz Estevez, M, Towfic, F, Flynt, E, Pierceall, W, Royston, D, Yong, KL, Ramasamy, K, Vyas, P, Thakurta, A
Publicat 2022Journal article